Statements (134)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:affects |
can include chronic fatigue
can include liver damage |
| gptkbp:antiviral_therapy |
can lead to sustained virologic response
|
| gptkbp:cause |
gptkb:virus
|
| gptkbp:clinical_trial |
ongoing for new treatments
ongoing for new therapies exist in treatment access and outcomes |
| gptkbp:co-morbidities |
often present with other diseases
|
| gptkbp:community_health |
aim to reduce transmission
screening recommended for high-risk groups significant global health issue |
| gptkbp:community_support |
can aid in recovery and management
|
| gptkbp:condition |
liver disease
extrahepatic manifestations |
| gptkbp:customs |
associated with drug use
|
| gptkbp:data_usage |
higher in certain populations
|
| gptkbp:diagnosis |
blood test
HCV RNA test anti-HCV antibody test |
| gptkbp:direct-acting_antivirals |
effective treatment option
|
| gptkbp:discovery |
discovered in 1989
|
| gptkbp:diseases |
often asymptomatic
may require lifestyle changes can lead to liver cancer can lead to liver cirrhosis may be asymptomatic HIV co-infection is common may require lifelong monitoring often requires lifestyle changes can resolve spontaneously requires long-term management HIV co-infection common HBV common in HCV patients HIV common in HCV patients |
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:economic_policy |
impact access to treatment
|
| gptkbp:epidemiology |
varies by region
affects millions worldwide studied globally for patterns and trends |
| gptkbp:fibrosis_assessment |
Fibro Scan is a non-invasive method
|
| gptkbp:fibrosis_score |
used to evaluate liver health
|
| gptkbp:financial_support |
available for those affected
available through various organizations available for those undergoing treatment |
| gptkbp:funding |
increased in recent years
increased for hepatitis research. |
| gptkbp:genetic_diversity |
high among different genotypes
|
| gptkbp:genotype_1 |
most common genotype in the US
|
| gptkbp:genotype_2 |
less common genotype
|
| gptkbp:genotype_3 |
associated with liver disease
|
| gptkbp:genotype_4 |
more common in the Middle East
|
| gptkbp:genotype_5 |
more common in South Africa
|
| gptkbp:genotype_6 |
more common in Southeast Asia
|
| gptkbp:genotype_distribution |
varies by region
|
| gptkbp:genotypes |
six genotypes
six main genotypes |
| gptkbp:global_burden |
significant public health issue
|
| gptkbp:goal |
eliminate HCV by 2030
|
| gptkbp:grooming_needs |
monitored during treatment
|
| gptkbp:healthcare |
varies by country
can be high due to chronic management important for ongoing care |
| https://www.w3.org/2000/01/rdf-schema#label |
HCV
|
| gptkbp:immune_response |
can be variable among individuals
|
| gptkbp:infected_population |
includes diverse demographics
|
| gptkbp:is_a_resource_for |
available for support and information
|
| gptkbp:is_involved_in |
available for patients
|
| gptkbp:is_tested_for |
HCV RNA test
HCV antibody test |
| gptkbp:is_vulnerable_to |
no vaccine available
no effective vaccine available |
| gptkbp:liver_biopsy |
used to assess liver damage
|
| gptkbp:liver_cancer_risk |
increases with chronic infection
|
| gptkbp:liver_function_tests |
used to monitor liver health
|
| gptkbp:liver_transplant |
may be necessary in severe cases
possible treatment for severe cases |
| gptkbp:liver_transplantation |
may be necessary for advanced liver disease
|
| gptkbp:patient_education |
important for management
crucial for management important for understanding the disease |
| gptkbp:post-transplant_treatment |
required to prevent recurrence
|
| gptkbp:post-treatment_monitoring |
important for detecting relapse
|
| gptkbp:prevalence |
approximately 71 million infected worldwide
|
| gptkbp:prevention |
safe sex practices
avoid sharing needles screening blood donations |
| gptkbp:provides_guidance_on |
varies by country
updated regularly by health organizations |
| gptkbp:public_awareness |
important for prevention
increased through campaigns aim to reduce stigma and promote testing |
| gptkbp:research |
ongoing for vaccine development
|
| gptkbp:research_focus |
vaccine development
improved treatment options |
| gptkbp:risk_factor |
multiple sexual partners
intravenous drug use blood transfusions before 1992 healthcare exposure sharing personal items tattooing with unsterile equipment mother to child transmission |
| gptkbp:rna_virus |
yes
|
| gptkbp:scientific_classification |
gptkb:World_Health_Organization
hepatitis virus |
| gptkbp:screenings |
high-risk populations
for individuals born between 1945 and 1965 for high-risk populations |
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea insomnia |
| gptkbp:sustained_virologic_response |
indicates cure
|
| gptkbp:symptoms |
fatigue
nausea abdominal pain jaundice loss of appetite can be mild or severe |
| gptkbp:transmission |
blood-to-blood contact
|
| gptkbp:treatment |
antiviral medications
over 95% with direct-acting antivirals improved with early detection and treatment includes direct-acting antivirals includes interferon and ribavirin over 95% with modern therapies |
| gptkbp:treatment_adherence |
critical for successful outcomes
|
| gptkbp:treatment_cost |
can be high in some regions
|
| gptkbp:who_guidelines |
focus on elimination by 2030
|
| gptkbp:bfsParent |
gptkb:HIV-2
gptkb:hepatitis_B_virus gptkb:Tibotec |
| gptkbp:bfsLayer |
5
|